

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

Strington, D.C. 20231

APPL	ICATION NO.	FILING DATE	FIRST NAMED INVENTOR				ATTORNEY DOCKET NO.
09	/110,720	07/07/98	BI	LLING-MEDEL		P	6130.US.P1
Γ	HM12/0203 STEVEN F WEINSTOCK ABBOTT LABORATORIES D-377/AP6D			HM12/0203	٦	EXAMINER STUCKER, J	
AB						ART UNIT	PAPER NUMBER
10	O ABBOTT	PARK ROAD K IL 60064	_၁ടററ			1648	5
HD	DUII CHN	V 1F 00004.	-3300			DATE MAILED:	02/03/99

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

Application No. 09/<del>100</del>,720

Applicant(s)

Billing-Medel et al.

Office Action Summary

Examiner

Jeffrey Stucker

Group Art Unit 1648

	T THE RELIGIOUS CO.
Responsive to communication(s) filed on	·
☐ This action is <b>FINAL</b> .	
☐ Since this application is in condition for allowance exc in accordance with the practice under Ex parte Quaylo	cept for formal matters, prosecution as to the merits is closed to the merits in the merits in the merits is closed to the merits in the m
is longer, from the mailing date of this communication. I	is set to expire1 month(s), or thirty days, whichever Failure to respond within the period for response will cause the Extensions of time may be obtained under the provisions of
Disposition of Claims	
X Claim(s) <u>1-44</u>	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
Claim(s)	is/are rejected.
	is/are objected to.
	are subject to restriction or election requirement.
Application Papers  See the attached Notice of Draftsperson's Patent II The drawing(s) filed on	is approved disapproved.  is approved disapproved.  priority under 35 U.S.C. § 119(a)-(d).  propies of the priority documents have been  prial Number)  com the International Bureau (PCT Rule 17.2(a)).
Attachment(s)	
<ul> <li>□ Notice of References Cited, PTO-892</li> <li>□ Information Disclosure Statement(s), PTO-1449, F</li> <li>□ Interview Summary, PTO-413</li> </ul>	Paper No(s)
<ul> <li>□ Notice of Draftsperson's Patent Drawing Review,</li> <li>□ Notice of Informal Patent Application, PTO-152</li> </ul>	PTO-948
SEE OFFICE ACTIO	ON ON THE FOLLOWING PAGES

Serial Number: 09/110720 Page 2

Art Unit: 1648

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1-10, 35, and 40-42, drawn to methods of detecting nucleic acid sequences, classified in Class 435, subclass 6.

II. Claims 11-14, 33, 34, 38, and 39, drawn to purified nucleic acid sequences, classified in Class 536, subclass 23.1.

III. Claims 15, 16, and 30, drawn to recombinant expression system and transfected cells, classified in Class 435, subclass 325.

IV. Claims 17-19, 21, 22, and 36, drawn to a polypeptide and a kit containing the polypeptide, classified in Class 530, subclass 350.

V. Claims 20, 23, 24, and 37, drawn to an antibody and a kit containing the antibody, classified in Class 530, subclass 387.1.

VI. Claim 25, drawn to a method of producing a peptide, classified in Class 435, subclass 325.

VII. Claims 26, 27, and 43, drawn to a method for detecting a polypeptide, classified in Class 435, subclass 7.1.

VIII. Claims 28, 29, and 44, drawn to a method for detecting an antibody, classified in Class 435, subclass 7.1.

IX. Claim 31, drawn to a first method of producing an antibody, classified in Class 424, subclass 277.1.

Serial Number: 09/110720 Page 3

Art Unit: 1648

X. Claim 32, drawn to a second method of producing an antibody, classified in Class 435, subclass 344.

The inventions are distinct, each from the other because of the following reasons:

The invention of Groups I, VI, VII, VIII, IX, and X are directed to methods and Groups II, III, IV, and V are directed to compositions which are patentably distinct.

Each of the method groups is distinct from the other because the methods each have different starting materials, reagents, and expected outcomes, e.g., methods of detecting and methods of producing.

Each of the composition groups is directed to different compositions that have different chemical structures and different physiological characteristics and are produced differently.

Because these inventions are distinct for the reasons given above and have acquired separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: each of SEQ ID NOs 1-16 and 31-35.

Serial Number: 09/110720

Art Unit: 1648

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or

Serial Number: 09/110720

Art Unit: 1648

admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Papers related this application may be submitted to Group 1648 by facsimile transmission. Papers should be faxed to Group 1648 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989).

The Group 1648 Fax numbers are: (703) 308-4242 and (703) 305-3014.

Unofficial communications may be faxed to: (703) 308-4426.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Stucker whose telephone number is (703) 308-4237. The examiner can normally be reached Monday to Thursday from 7:00am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Chris Eisenschenk, Ph.D., can be reached on (703) 308-0452.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JEFFREY STUCKER
PRIMARY EXAMINER